fda tirzepatide injection shortage resolved oct 2 2024 Lilly's weight-loss drug removed from FDA's list FDA declares shortage over for
Description
Documentation was based on information from full-text publications, including preclinical and clinical trials, meta-analyses, and reviews on this topic
[4] A separate 2024 randomized double-blind trial in people with HIV taking modern integrase-inhibitor regimens found that tesamorelin 2 mg daily significantly reduced both visceral and hepatic fat versus placebo, again without worsening glycemic control in that analysis
Cronstein, B
These include the following
Tirzepatide was titrated up to a maximum dose of 10 mg or 15 mg
doi: 10.1016/j.biopha.2019.108667 53 KrasnerNMIdoYRudermanNBCacicedoJM
